(433) DECON- a novel platform for Sustained Ocular Delivery of Corticosteroids
Introduction: Vision loss caused by corneal inflammation, stemming from viral or non-viral infections, is a significant public health concern. While topical corticosteroids are commonly used to manage this inflammation, their efficacy is limited due to ocular barriers. Conventional eye drops deliver only 0.07%–4% of the dose to the eye, necessitating frequent, high-concentration doses. A topical drug delivery system that overcomes these barriers, ensures sustained release, and resides in the eye for longer durations is critically needed.
Learning Objectives:
Upon completion, the participant will be able to develop a formulation that is patient compliance.
come up with a formulation of eye drops that would minimize the frequency of doses.
the eye-drop formulation warrants broader ophthalmic applications
